Evidence map›Paper›PMID 28139542›Full record

ArticleThe Indian journal of medical research2016

An audit of colistin use in neonatal sepsis from a tertiary care centre of a resource-limited country.

Bonny Jasani, Sridharan Kannan, Ruchi Nanavati, Nithya J Gogtay, Urmila Thatte

Open access · diamondAbstract read
In one paragraph

Article in The Indian journal of medical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Colistin therapy and survival outcomes in neonatal carbapenem-resistant gram-negative sepsis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Article
  4. Appropriate use of colistin in neonates, infants and children: Interim guidance.Southern African journal of infectious diseases · 2023
    Article
  5. Extensive outbreak of colistin resistant, carbapenemase (blaAntimicrobial resistance and infection control · 2022
    Article
  6. Safety and efficacy of colistin and fluoroquinolone in neonatal persistent late-onset sepsis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021
    Article
  7. A Case of Sepsis Due to Carbapenem-ResistantInfection and drug resistance · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Bonny JasaniDepartment of Neonatology, Seth GS Medical College & KEM Hospital, Mumbai, India.
Sridharan KannanDepartment of Clinical Pharmacology, Seth GS Medical College & KEM Hospital, Mumbai, India.
Ruchi NanavatiDepartment of Neonatology, Seth GS Medical College & KEM Hospital, Mumbai, India.
Nithya J GogtayDepartment of Clinical Pharmacology, Seth GS Medical College & KEM Hospital, Mumbai, India.
Urmila ThatteDepartment of Clinical Pharmacology, Seth GS Medical College & KEM Hospital, Mumbai, India.
King Edward Memorial Hospital and Seth G.S. Medical College · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

objectivesSepsis due to multidrug-resistant Gram-negative pathogens is a challenge for clinicians and microbiologists and has led to use of parenteral colistin. There is a paucity of data regarding safety and efficacy of intravenous colistin use in neonates. The objective of this retrospective analysis was to study the efficacy and safety of intravenous colistin in the treatment of neonatal sepsis.

methodsAn audit of the data from neonates, admitted to a neonatal intensive care unit of a tertiary care hospital during January 2012 to December 2012, and who received intravenous colistin was carried out.

resultsSixty two neonates received intravenous colistin (52 preterm and 10 term) for the treatment of pneumonia, bloodstream infections and meningitis. The isolated pathogens in decreasing order of frequency were Acinetobacter baumannii, Klebsiella pneumonia and Pseudomonas aeruginosa. Of the total 62 neonates, 41 (66.12%) survived and 21 (33.87%) died. Significantly higher mortality was observed in neonates with lower body weights (P < 0.05). A significant association of mortality was found in those with sepsis due to Klebsiella species. Only one of seven with this infection survived as against 15 of the 23 who grew other organisms [P = 0.03; crude odds ratio = 11.25 (1.2, 110.5)]. None of the neonates developed neurotoxicity or nephrotoxicity. INTERPRETATION &

conclusionsThis retrospective study in neonates with sepsis showed that intravenous colistin was safe and effective in the treatment of neonatal sepsis. Further, well-controlled, prospective clinical trials need to be done to corroborate these findings.

Indexed as

Acinetobacter baumanniiAdministration, IntravenousColistinFemaleHumansInfant, NewbornKlebsiella pneumoniaeMaleMeningitisNeonatal SepsisPneumoniaPseudomonas aeruginosaTertiary Care CentersColistin

Identifiers

PMID28139542
PMCPMC5320849
OpenAlexW2574747543

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.